

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
12 February 2004 (12.02.2004)

PCT

(10) International Publication Number  
WO 2004/012705 A1

(51) International Patent Classification<sup>7</sup>: A61K 9/08, 31/495

(21) International Application Number: PCT/CH2003/000523

(22) International Filing Date: 30 July 2003 (30.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 1357/02 31 July 2002 (31.07.2002) CH

(71) Applicant (for all designated States except US): PHAFAG AG [LI/LI]; Gewerbeweg 143, FL-9486 Schaanwald (LI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BIEBER-SCHULTE, Werner [LI/LI]; Grasgarten 505, LI-9492 Eschen (LI). EHRENBERGER, Klaus [AT/AT]; Günthergasse 1, A-1090 Wien (AT).

(74) Agents: HASLER, Erich et al.; Riederer Hasler & Partner, Patentanwälte AG, Kappelestrasse 15, FL-9492 Eschengaz (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/012705 A1



(57) Abstract: A new pharmaceutical formulation, especially for trans-tympanic or intra-trans-tympanic administration, containing a quinoxalin-2-one compound of the formula (I) in which R1 and R2, independently of one another, are hydrogen, methyl-, ethyl-, propyl-, butyl- or R1 and R2 together are a cyclo-alkyl compound; R3 is methoxy, ethoxy, hydroxy, hydrogen, C1-C4 alkyl or halogen, and n = 1, 2 or 3, or a pharmaceutically compatible salt of the afore-mentioned derivatives, and in addition an effective amount of a permeability accelerator of the afore-mentioned quinoxalin-2-one compound, as well as, if necessary, a pharmaceutically compatible a solvent.

- 1 -

### **A Pharmaceutical Formulation and its Use in the Treatment of Inner Ear Diseases**

The invention concerns a pharmaceutical formulation as well as the use of this formulation for the treatment especially of inner ear diseases.

5

Quinoxaline-2-one derivatives have been known since the 60's or early 70's as active pharmaceutical compounds. An important representative of the quinoxaline-2-one derivatives is Caroverin (= non-proprietary name) whose correct chemical name is 1-diethylaminoethyl-3-(p-methoxybenzyl)-1,2-dihydro-quinoxaline-2-one.

10

EP-A-0 542 689 describes the use of quinoxaline-2-one derivatives for the production of effective pharmaceutical, neuro-protective compounds for the treatment of neuro-toxicities and functional disturbances of the central nervous system. According to EP-A-0 542 689, Caroverin is especially useful in the treatment of cochlear post-synaptic tinnitus. The 15 previously described, pharmaceutically effective quinoxaline-2-one derivatives should be able to be administered orally, rectally or parenterally. In a clinical trial on the treatment of cochlear post-synaptic tinnitus, the patient was administered between 70 and 160 mg of Caroverin dissolved in 100 ml of physiological saline, intravenously.

20

WO 99/66931 proposes the use of quinoxaline derivatives for the treatment of diseases caused by the presence of free-radicals of cell-oxygen metabolism, for stimulation of nerve cell synthesis and for antagonizing glutamate receptors, etc. According to WO 99/66931, the quinoxaline derivates referred to can be administered by any known method, especially oral, trans-dermal, topical and parenteral, although the intra-venous route is preferred. The 25 topical administration of Caroverin in the form of an ointment has been described for the alleviation of sun injuries as well as of skin inflammation caused by oxidation. For these indications, it is a matter of treating superficially and locally with the active medication, which need not necessarily penetrate the blood circulation system for the activity to be effective. In the example of its use mentioned in WO 99/66931, Caroverin was 30 administered once or more frequently to the patient intravenously in relatively high doses. The dosage used was between 160 mg to 1000 mg per day. For many indications, the degree of effectiveness of Caroverin was strongly dependent on the dosage given, and was

- 2 -

only satisfactory at high doses. For example, to achieve a neuro-regenerative effect, it was necessary to administer higher doses of Caroverin.

In view of the very high doses required, the specialists did not previously consider the 5 administration of Caroverin by a trans-dermal route, since with trans-dermal administration, it is well known that only relatively small active amounts may be introduced into the blood stream. Trials undertaken by the inventor have shown also that Caroverin only has a limited permeability through the skin.

10 In addition, new trials by the inventor have shown that Caroverin is not indicated for the treatment of all forms of tinnitus. Apart from cochlear post-synaptic tinnitus, which, according to EP 0 542 689, is treatable by infusion of Caroverin, it has been observed that a muscular tinnitus (also known as myognathic tinnitus) is not responsive to the intravenous administration of Caroverin. Muscular or myognathic tinnitus is identified by 15 imparting an electrical charge to the chewing musculature, whereby the intensity and frequency of the symptoms of tinnitus can be altered. Myognathic tinnitus can substantially be caused to disappear when the tendon bundles of the middle ear musculature that operates the chain of auditory ossicles are surgically sectioned (tenotomy). The precise mechanism involved in this effect is still unclear.


20 Morbus Menière, named after the French doctor of the same name, is a relatively rare disease, the symptoms of which are turning-giddiness, ringing in the ears and noise-sensitive hearing deficiency. The disease appears from time to time, and is usually accompanied by severe nausea and vomiting. After some time, a pan-cochlear loss of 25 hearing develops. At the present time, the recommended medical therapies for Morbus Ménière are highly unsatisfactory.

It is, therefore, an object of this invention, to make available an improved pharmaceutical preparation or formulation for the treatment of inner ear diseases. An object of this 30 invention is to provide an improved formulation that can also be administered by the patient himself. Yet another object is to make available a medicine and/or a pharmaceutical formulation for the treatment also of the so-called muscular or myognathic

- 3 -

tinnitus, Morbus Ménière, labyrinthine vertigo and impairment of hearing, especially such associated with speech comprehension deficiency.

According to the present invention, the object is achieved by means of a pharmaceutical 5 formulation, especially for trans-tympanic or intra-transmypanic administration, that contains a quinoxalin-2-one derivative of the formula



10 in which R<sub>1</sub> and R<sub>2</sub>, independently of one another, are hydrogen, methyl-, ethyl-, propyl- or butyl-, or R<sub>1</sub> and R<sub>2</sub> together form a cyclo-alkyl compound.  
R<sub>3</sub> is methoxy, ethoxy, hydroxy, hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl or halogen; and n = 1, 2 or 3, or a pharmaceutically compatible salt of the aforesaid derivatives; and, further containing an active amount of a compound which, with reference to the above- 15 mentioned quinoxalin-2-one derivatives, works as a permeability accelerator or carrier in respect of the afore-mentioned quinoxalin-2-one derivatives; as well as, if required, a pharmaceutically compatible solvent.

The inventor was surprised to discover that, with the help of a suitable permeability 20 accelerator, or activator, and carrier system, respectively, a formulation could be identified that could provide trans-tympanic administration, and that was already highly effective with low dosages. This result was completely unexpected since it had been necessary to administer relatively high doses of quinoxalin-2-one derivatives intravenously in the case of the abovementioned indications. Therefore, it could not have been expected that the 25 quinoxalin-2-one derivatives together with a suitable permeability accelerator or carrier system were already effective at much lower dosages when the novel formulation was applied through the tympanum.

- 4 -

Especially effective are the quinoxalin-2-one derivatives in which the R1 and R2 substituents are an ethyl group, where n = 2, and in which R3 is a methoxy group, so that the molecule is 1-diethylaminoethyl-3-(p-methoxybenzyl)-1,2-dihydro-quinoxalin-2-one (non-proprietary name: Caroverin) or a pharmaceutically compatible salt thereof.

5 Furthermore, quinoxalin-2-one derivatives are also effective in which the R1 and R2 substituents are an ethyl group where n = 2, and R3 is a hydroxy group, so that the molecule is 1-diethylaminoethyl-3-(p-hydroxybenzyl)-1,2-dihydro-quinoxalin-2-one or a pharmaceutically compatible salt thereof.

10 Advantageously, the permeability accelerator used in the formulation is one of the following compounds: dimethyl sulphoxide, mono-glyceride, ethyl- or methyl-palmitic acid ester, fatty acids, fatty acid esters, fatty acid alcohols, substituted dialkyl fatty acids having 8 to 14 carbon atoms, N-methyl pyrrolidone, N-methyl-2-pyrrolidone oleic acid, propylene glycol, diethylene glycol, the mono-alkyl ether or carboxy-methyl ether of poly-15 ethylene glycol, propylene glycol fatty acid ester, lauryl acetate, N,N-dialkyl lauramide, histamine, a dialkyl lauramide/dimethyl formamide mixture, dimethyl acetamide, N,N-diethyl-m-toluamide, ethylene glycol monomethyl ether, isopropyl myristate, isopropyl palmitate, propylene glycol and oleic acid or oleyl alcohol, 2-pyrrolidone and dimethyl formamide, lauric acid, linoleic acid, lauryl acetate, sodium oleate, glycerine mono-oleate, 20 urea, 1-bisabolol. Also possible is the use of a combination of 2 or more of the aforementioned permeability accelerators.

In a preferred formulation, the permeability accelerator used is at least dimethyl sulphoxide or propylene glycol. It has been shown that dimethyl sulphoxide is a good solvent and, 25 surprisingly, a good permeability accelerator for quinoxalin-2-one derivatives, especially for Caroverin. Furthermore, dimethyl sulphoxide can be added in fairly high concentrations. The content by weight of dimethyl sulphoxide in the formulation preferably comprises between 5 and 50%, but can also be higher. Advantageously, the formulation contains, together with dimethyl sulphoxide, at least another second permeability accelerator. This can be a member of the above-mentioned group of 30 permeability accelerators. By the addition of at least one further permeability accelerator, the content by weight of dimethyl sulphoxide can be correspondingly reduced. In this way, the risk is reduced that the administration of the formulation causes skin irritation.

- 5 -

Preferably, the second permeability accelerator is a glycol compound such, for example, as an ethylene- and/or propylene glycol compound.

Advantageously, the ratio by weight of quinoxalin-2-one derivative to the permeability

5 accelerator is between 1:2 and 1:500, preferably between 1:20 and 1:100. As the solvent, for example, glycerine or another physiologically compatible compound, such as water, can be used.


10 An advantageous formulation uses a nanoemulsion or liposomes, which contain the said quinoxalon-2-one compound according to Formula (I), as the permeation accelerator or carrier. Expediently, the nanoemulsion or the liposomes contain a membrane-forming molecule and a coemulsifier besides the said quinoxalon-2-one derivatives.

15 Substances which make it possible to form two-layer systems (so-called "bilayers") are preferably used as the membrane-forming molecule. A phospholipid is preferably used as the membrane-forming molecule. It may be a hydrogenated or partially hydrogenated phospholipid. A naturally or artificially produced lecithin is preferably used. The latter may, for example, be obtained from soy beans or hen's eggs. Examples of phospholipids are phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, 20 phosphatidylinositol, phosphatidylserine and sphingomyelin. The acyl chain may be either saturated or unsaturated, and may have from 12 to 22, preferably from 14 to 18 C atoms. Other liposome-forming membrane lipids such as glycolipids, ceramides, gangliosides and cerebrosides may be used instead of, or partially instead of, phospholipids.

25 The lipids may be derived from natural plant, animal or microbiological sources, synthetically produced or partially synthetically produced, inclusive of monoacyl phospholipids derived from polyethylene glycol (PEG), for example pegylated monoacyl phosphatidylethanolamine.

30 According to a particularly preferred embodiment, a phospholipid of the formula

- 6 -



in which

R1 denotes  $\text{C}_{10}\text{-}\text{C}_{20}$  acyl;

5 R2 denotes hydrogen or  $\text{C}_{10}\text{-}\text{C}_{20}$  acyl

R3 denotes hydrogen, 2-trimethylamino-1-ethyl, 2-amino-1-ethyl, unsubstituted  $\text{C}_1\text{-}\text{C}_5$  alkyl or  $\text{C}_1\text{-}\text{C}_5$  alkyl substituted with one or more carboxyl, hydroxy or amino groups; the inositol or glyceryl group, or salts of these compounds,  
is used as the membrane-forming molecule.

10 The  $\text{C}_{10}\text{-}\text{C}_{20}$  acyl is preferably a straight-chained  $\text{C}_{10}\text{-}\text{C}_{20}$  alkanoyl having an even number of C atoms or straight-chained  $\text{C}_{10}\text{-}\text{C}_{20}$  alkanoyl having one or more double bonds and an even number of C atoms. Straight-chained  $\text{C}_{10}\text{-}\text{C}_{20}$  alkanoyls having an even number of C atoms are, for example, n-dodecanoyl, n-tetradecanoyl, n-hexadecanoyl or n-octadecanoyl. Straight-chained  $\text{C}_{10}\text{-}\text{C}_{20}$  alkanoyls having a double bond and an even number of C atoms are, for example, 6-cis- or 6-trans-, 9-cis- or 9-trans-dodecenoyl, -tetradeценoyл, -hexadecenoyl, -octadecenoyl or -icosenoyl, in particular 9-cis-octadecenoyl (oleoyl), and 9,12-cis-octadecadienoyl or 9,12,15-cis-octadecatrienoyl.

15

A phospholipid of Formula (II) in which R3 denotes 2-trimethylamino-1-ethyl is referred to by the trivial name lecithin, and a phospholipid of Formula (II) in which R3 denotes 2-amino-1-ethyl is referred to by the trivial name cephalin. For example, naturally occurring cephalin or lecithin having different or identical acyl groups, or mixtures thereof, are suitable.

25 The membrane-forming component is preferably used in a concentration of about 0.1 to 30% by weight, expressed in terms of the total weight of membrane-forming component, emulsifier and active substance.

One of the following coemulsifiers, or an emulsifier mixture of two or more of the coemulsifiers listed below, may be used as the emulsifier:

5 Alkali metal, ammonium and aminium salts of fatty acids, for example lithium, sodium, potassium, ammonium, triethylamine, ethanolamine, diethanolamine or triethanolamine salts. Sodium, potassium or ammonium (NR<sub>1</sub>R<sub>2</sub>R<sub>3</sub>) salts are preferred, R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> independently of one another denoting hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>1</sub>-C<sub>4</sub> hydroxyalkyl.  
Alkyl sulfates such as, for example, sodium dodecyl sulphate.

10 Salts of bile acid, for example sodium cholate, sodium glycocholate and sodium taurocholate;

partial fatty acid esters of sorbitan, for example sorbitan monolaurate; sugar esters, for example sucrose monolaurate; fatty acid partial glycerides, for example lauric acid monoglyceride; polyglycerol esters of fatty acids;

15 propylene glycol esters of fatty acids; lactic acid esters of fatty acids, for example sodium stearoyl-lactyl-2-lactate; proteins, for example casein.

20 Emulsifiers of the polyoxyethylene type are more particularly preferred. Examples of such emulsifiers are:

- polyethoxylated sorbitan fatty acid esters, for example polysorbate 80;

- polyethoxylated vitamin E derivates, for example vitamin E polyethylene glycol 1000 succinate;

- polyethoxylated fatty acid partial glycerides, for example diethylene glycol monostearate;

25 - polyethoxylated carbohydrates;


- block polymers of ethylene oxide and propylene oxide, for example poloxamer 188.

30 The emulsifier is advantageously present in the formulation at a concentration of about 1 to about 50% by weight, expressed in terms of the total weight of the membrane-forming component, the emulsifier and the active substance. The quinoxalin-2-one compound is present in the formulation at a concentration of about 0.1 to 70% by weight, expressed in

terms of the total weight of the components (membrane-forming component, emulsifier and quinoxalin-2-one compound).

The subject of the present invention also comprises the use of a quinoxalin-2-one

5 derivative of the formula:



in which R1 and R2, independently of one another, are hydrogen, methyl-, ethyl-, propyl- or butyl-, or R1 and R2 together form a cyclo-alkyl compound;

10 R3 is the methoxy, ethoxy, hydroxy, hydrogen, a C1-C4 alkyl or halogenatom, and n = 1, 2 or 3;

or a pharmaceutically compatible salt of the afore-mentioned quinoxalin-2-one compound; and

15 an effective amount of a compound that is a permeability accelerator, also in the form of a suitable carrier like a nanoemulsion or liposomes, in respect of the above-mentioned quinoxalin-2-one derivatives for the manufacture of a pharmaceutical formulation that can be administered through the tympanum for the treatment of inner-ear diseases. Preferably, Caroverin or a salt compound of Caroverin is used in the formulation. Salt compounds have the advantage that they are more readily soluble in divers solvents.

20 A further subject of the present invention is the use, in accordance with the Claims 30 to 37, for the treatment of the hitherto unknown indications, such as the treatment of myognathic tinnitus, Morbus Ménière, labyrinthine vertigo or speech discrimination impediments together with hearing impediments. These are new indications for 25 quinoxalin-2-one derivatives and, in particular, for Caroverin. For the aforementioned indications the quinoxalin-2-one derivatives can be used also in accordance with a known form of administration like, e.g. intravenous injection. Preferably, the quinoxalin-2-one derivatives, however, are administered in a formulation together with a permeability

- 9 -

accelerator or in a carrier system in the form of liposomes or a nanoemulsion according to the above description.

The formulation according to the invention is preferably administered in a liquid form.

5 Aqueous formulations as well as non aqueous ones can be used. Advantageously the viscosity of the formulation is between 5000 and 25000 mPas (milli-Pascal per second), preferably between 15000 and 20000 mPas, so that a longer period of administration of the active ingredient into the inner ear is achieved. The part by weight of quinoxalin-2-one derivative used is preferably between about 0.5% and 12%.

10 The treatment of a patient takes place as follows: An absorbable material such, for example, as a wick of about 2 mm diameter and 2 to 3 cm in length is soaked with the inventive formulation. The soaked wick is then inserted into the ear so that it lies against the tympanic membrane. Depending on the concentration of the solution used, the therapy 15 lasts between 3 and 24 hours. Depending on the condition of the disease, the above described treatment is continued by the additional administration of a specific number of drops of the active formulation, such, for example, as 3 – 4 drops every second day.

20 In the case where the formulation is a nanoemulsion, the formulation can also be applied directly onto tympanum.

Alternatively, the formulation can also be administered intra-trans-tympanically. For this form of administration of active substances, a canula or drainage tubule that reaches into the middle ear, is used and the active substances are administered via the drainage tubule.

25

#### Examples of the Formulation

Three examples of the non-aqueous formulations are as follows:

##### Example 1

0.5% of Caroverin  
20% of dimethyl sulphoxide  
30% of propylene glycol  
50% of glycerine

##### Example 2

0.5% of Caroverin  
20% of dimethyl sulphoxide  
30% of propylene glycol  
50% of gel

- 10 -

Example 3

10% of Caroverin hydrochloride  
20% of dimethyl sulphoxide  
30% of propylene glycol  
40% of glycerine

Example 4

1 % of Caroverin  
3% of acetone  
96% of propylene glycol

The viscosity of the different trial solutions (formulations) is, preferably, between 5000 and 25000 mPas, more preferably between 15000 – 20000mPas.

5

The following example is of an aqueous formulation with a thickening agent:

Example 5

10 1% of Caroverin hydrochloride  
20% of dimethyl sulphoxide  
30% of propylene glycol  
48% of water  
1% of thickening agent (PVM/MA decadiene cross-polymer).

15

The viscosity of the solution is preferably increased by the addition of a thickening agent, so that, during the drop-wise administration of the solution into the outer auditory meatus the solution stays as long as possible on the tympanic membrane without running out.

Because of the good adhesion of the formulation on the tympanic membrane, a long lasting  
20 administration of the active ingredient into the inner ear is ensured.

- 11 -

Preparation of a nanoemulsion / liposomes


In order to produce the formulation, the emulsifier and the quinoxalin-2-one compound are mixed to form a homogenous liquid phase, optionally while heating. The phospholipid is

5 dissolved in this phase, optionally with the aid of a solubility promoter, for example ethanol. This results in a homogenous solution. It may then be diluted with water to the intended concentration of active substance.

- 12 -

Claims

1. A pharmaceutical formulation, especially for the trans-tympanic or intra-trans-tympanic administration, according to which the formulation contains a quinoxalin-5-2-one derivative of the formula



in which R1 and R2, independently of one another, are hydrogen, methyl-, ethyl-, propyl- or butyl- groups, or R1 and R2 together form a cyclo-alkyl compound, 10 R3 is methoxy-, ethoxy-, hydroxy-, hydrogen, C1-C4-alkyl- or halogen; and n = 1, 2 or 3; or a pharmaceutically compatible salt of the aforesaid derivatives; and, in addition, containing an effective amount of a compound that acts as a permeability accelerator or carrier in respect of the afore-mentioned quinoxalin-2-one derivatives; as well as, if necessary, a pharmaceutically compatible solvent.

15

2. A pharmaceutical formulation as claimed in Claim 1, according to which R1 and R2 are ethyl groups; n = 2, and R3 is a methoxy group, so that the molecule is 1-diethylaminoethyl-3-(p-methoxybenzyl)-1,2-dihydro-quinoxalin-2-one (INN: Caroverin), or a pharmaceutically compatible salt thereof.

20

3. A pharmaceutical formulation as claimed in Claim 1, according to which R1 and R2 are ethyl groups; n = 2; and R3 is a hydroxy group, so that the molecule is 1-diethylaminoethyl-3-(p-hydroxy-benzyl)-1,2-dihydro-quinoxaline-2-one or a pharmaceutically compatible salt thereof.

25

4. A pharmaceutical formulation as claimed in any one of the Claims 1 to 3, according to which the permeation accelerator or carrier comprises at least one of the

following compounds: Dimethyl sulphoxide, monoglyceride, ethyl- or methyl-palmitic acid ester, fatty acids, fatty acid esters, fatty acid alcohols, substituted di-alkyl fatty acids having 8 to 14 carbon atoms, N-methyl-pyrrolidone, N-methyl-2-pyrrolidone, oleic acid, propylene glycol, diethylene glycol, the mono-alkyl ether or carboxy-methyl ether of polyethylene glycol, propylene glycol fatty acid ester, 5 lauryl acetate, N,N-dialkyl lauramide, N,N-dialkyl lauramide/dimethyl formamide mixture, dimethyl acetamide, N,N-diethyl-m-toluamide, histamine, ethylene glycol monomethyl ether, isopropyl myristate, isopropyl palmitate, propylene glycol and oleic acid or oleic alcohol, 2-pyrrolidone and dimethyl formamide, lauric acid, 10 linoleic acid, lauryl acetate, sodium oleate, glycerine mono-oleate, urea and 1-bisabolol.

5. A pharmaceutical formulation as claimed in any one of the Claims 1 to 4, according to which the permeability accelerator used at least contains dimethyl sulphoxide or 15 propylene glycol.
6. A pharmaceutical formulation as claimed in any one of the Claims 1 to 5, according to which the part by weight of dimethyl sulphoxide in the formulation is between 5 and 50%.
- 20 7. A pharmaceutical formulation as claimed in any one of the Claims 1 to 6, according to which at least one further, second permeability accelerator is contained in combination with dimethyl sulphoxide.
- 25 8. A pharmaceutical formulation as claimed in any one of the Claims 1 to 7, according to which the second permeability accelerator is a glycol compound.
9. A pharmaceutical formulation as claimed in Claim 7 or 8, according to which the second permeability accelerator is ethylene- or propylene glycol.
- 30 10. A pharmaceutical formulation as claimed in any one of the Claims 1 to 9, according to which the ratio by weight of the quinoxalin-2-one derivative to the permeability

- 14 -

accelerator is between 1:2 and 1:500, preferably between 1:20 and 1:100.

11. A pharmaceutical formulation as claimed in any one of the Claims 1 to 10, according to which glycerine and/or water are used as the solvent.

5


12. A pharmaceutical formulation as claimed in any one of the Claims 1 to 11, according to which the viscosity of the formulation is between 5000 and 25000 mPas (milliPascal), preferably between 15000 and 20000 mPas.

10 13. A pharmaceutical formulation as claimed in any one of the Claims 1 to 4, according to which a nanoemulsion or liposomes, which contain the said quinoxalon-2-one compound according to Formula (I), are used as a permeation accelerator or carrier.

14. A pharmaceutical formulation as claimed in Claim 13, according to which the nanoemulsion or the liposomes contain the following compounds besides the said quinoxalon-2-one compound:

15 - a membrane-forming molecule and  
- a coemulsifier.

20 15. The use of a quinoxalin-2-one compound of the formula



according to which

25 R1 and R2, independently of one another, are hydrogen, methyl-, ethyl-, propyl- or butyl-, or R1 and R2 together form a cyclo-alkyl compound; R3 is methoxy, ethoxy, hydroxy, hydrogen, C1-C4 alkyl or halogen; and n = 1,2 or 3,

- 15 -

5 or a pharmaceutically compatible salt of the afore-mentioned quinoxalin-2-one compound, together with an effective amount of compound that acts as a permeability accelerator or carrier in respect of the quinoxalin-2-one compound, for the production of a pharmaceutical formulation for trans-tympanic or intra-trans-tympanic administration.

10 16. The use as claimed in Claim 15, according to which R1 and R2 are ethyl groups, n = 2 and R3 is a methoxy group, so that the molecule is 1-diethyl-aminoethyl-3-(p-methoxybenzyl)-1,2-dihydro quinoxalin-2-one or a pharmaceutically compatible salt thereof.

15 17. The use as claimed in Claim 15, according to which R1 and R2 are ethyl groups, n = 2 and R3 is a hydroxy group, so that the molecule is 1-diethyl-aminoethyl-3-(p-hydroxybenzyl)-1,2-dihydro quinoxalin-2-one or a pharmaceutically compatible salt thereof.

18. The use as claimed in any one of the Claims 15 to 17, according to which the permeability accelerator at least contains dimethyl sulphoxide or propylene glycol.

20 19. The use as claimed in Claim 18, according to which the part by weight of dimethyl sulphoxide used in the formulation is between 5 and 50%.

25 20. The use as claimed in any one of the Claims 15 to 19, according to which at least one further second permeability accelerator is contained in combination with dimethyl sulphoxide.

21. The use as claimed in Claim 20, according to which the second permeability accelerator used is a glycol compound.

30 22. The use as claimed in Claim 20 or 21, according to which the second permeability accelerator used is ethylene- and/or propylene glycol.

- 16 -


23. The use as claimed in any one of the Claims 15 to 22, according to which the ratio by weight of quinoxalin-2-one to the permeability accelerator is between 1:2 and 1:500, preferably between 1:20 and 1:100.
- 5 24. The use as claimed in any one of the Claims 15 to 23, according to which the solvent used is glycerine and/or water.
- 10 25. The use as claimed in any one of the Claims 15 to 17, according to which a nanoemulsion or liposomes, which contain the said quinoxalon-2-one compound according to Formula (I), are used as a permeation accelerator or carrier.
26. The use as claimed in Claim 25, according to which the nanoemulsion or the liposomes contain the following compounds besides the said quinoxalon-2-one compound:
  - 15 - a membrane-forming molecule and
  - a coemulsifier.
27. The use as claimed in any one of the Claims 15 to 24, according to which the formulation is liquid and the part by weight of the quinoxalin-2-one compound is 20 between 0.5% and 12%.
28. The use as claimed in any one of the Claims 15 to 27, according to which the formulation is used either as a non-aqueous or as an aqueous formulation.
- 25 29. The use as claimed in any one of the Claims 15 to 28, according to which it is used for the treatment of inner ear diseases.
- 30 30. The use as claimed in any one of the Claims 15 to 28, according to which it is used for the treatment of muscular or myognathic tinnitus.
31. The use as claimed in any one of the Claims 15 to 28, according to which it is used for the treatment of Morbus Ménière.

- 17 -

32. The use as claimed in any one of the Claims 15 to 28, according to which it is used for the treatment of speech-discrimination deficiency, especially in combination with hearing deficiency.

5 33. The use as claimed in any one of the Claims 15 to 28, according to which it is used for the treatment of labyrinthine vertigo.


34. The use of a quinoxalin-2-one compound of the formula



10

according to which R1 and R2, independently of one another, are hydrogen, methyl-, ethyl-, propyl- or butyl-, or R1 and R2 together are a cyclo-alkyl compound; R3 is methoxy, ethoxy, hydroxy, hydrogen, C1-C4 alkyl or halogen; and n = 1, 2 or 3, preferably Caroverin or a pharmaceutically compatible salt of the afore-mentioned quinoxalin-2-one compound, for the production of a medicine for the treatment of muscular or myognathic tinnitus.

15 20 35. The use of a quinoxalin-2-one derivative of the formula




- 18 -

according to which R1 and R2, independently of one another, are hydrogen, methyl-, ethyl-, propyl- or butyl- or R1 and R2 together are a cyclo-alkyl compound; R3 is methoxy, ethoxy, hydroxy, hydrogen, C1-C4 alkyl or halogen; and n = 1, 2 or 3, preferably Caroverin, or of a pharmaceutically acceptable salt of one of the aforementioned quinoxalin-2-one compounds for the production of a medicine for the treatment of Morbus Ménière.

5

36. The use of a quinoxalin-2-one derivative of the formula




10

In which R1 and R2, independently of one another, are hydrogen, methyl-, ethyl-, propyl-, butyl—or R1 together with R2 are a cyclo-alkyl compound; R3 is methoxy, ethoxy, hydroxy, hydrogen, C1-C4 alkyl, or halogen; and n = 1, 2 or 3, preferably Caroverin, or of a pharmaceutically compatible salt of the aforementioned quinoxalin-2-one derivative for the production of a medicine for the treatment of hearing deficiencies, especially such together with speech comprehension deficiencies.

15

- 19 -

37. The use of a quinoxalin-2-one derivative of the formula



5 in which R1 and R2, independently of one another, are hydrogen, methyl-ethyl-,  
propyl-, butyl- or R1 and R2 together are a cyclo-alkyl compound;  
R3 is methoxy, ethoxy, hydroxy, hydrogen, C1-C4 alkyl, or halogen, and  
n = 1, 2 or 3, preferably Caroverin, or of a pharmaceutically compatible salt of one  
of the afore-mentioned quinoxalin-2-one compounds for the production of a  
10 medicine for the treatment of labyrinthine vertigo.

38. The use according to any one of the claims 34 to 37, characterized in that the  
derivative is Caroverin.

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/CH 03/00523

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K9/08 A61K31/495

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 542 689 A (PHAFAG) 19 May 1993 (1993-05-19) cited in the application claims page 4, line 38 - line 41 page 4, line 47 - line 48 ---	1-38
A	EP 0 032 564 A (MEDICHEMIE) 29 July 1981 (1981-07-29) claims page 4 ---	1-38 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

27 October 2003

Date of mailing of the international search report

03/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CH 03/00523

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE WPI Section Ch, Week 198319 Derwent Publications Ltd., London, GB; Class A96, AN 1983-45789K XP002235212 & JP 58 057317 A (MITSUBISHI CHEM IND LTD) , 5 April 1983 (1983-04-05) abstract ----	1-38
A...	WO 99 66931 A (PHAFAG) 29 December 1999 (1999-12-29) cited in the application claims ----	1-38
A	WO 92 04011 A (ALZA) 19 March 1992 (1992-03-19) claims example 5 ----	1-38
A	WO 92 00729 A (ALZA) 23 January 1992 (1992-01-23) claims example 2 -----	1-38

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/CH 03/00523

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 542689	A 19-05-1993	EP 0542689 A1 AT 171374 T DE 69227088 D1 DE 69227088 T2 ES 2123546 T3 JP 6239747 A US 5563140 A	19-05-1993 15-10-1998 29-10-1998 02-06-1999 16-01-1999 30-08-1994 08-10-1996
EP 032564	A 29-07-1981	CH 653259 A5 CH 652928 A5 JP 56097228 A JP 56097226 A AU 542860 B2 AU 6584680 A DE 3047811 A1 EP 0032564 A1 IT 1174691 B JP 56161376 A BE 886874 A1 CH 646058 A5 ZA 8008087 A US 4339452 A	31-12-1985 13-12-1985 05-08-1981 05-08-1981 21-03-1985 16-07-1981 29-10-1981 29-07-1981 01-07-1987 11-12-1981 16-04-1981 15-11-1984 27-01-1982 13-07-1982
JP 58057317	A 05-04-1983	NONE	
WO 9966931	A 29-12-1999	AT 408837 B AT 106398 A WO 9966931 A1 CA 2336194 A1 CN 1309563 T EP 1087768 A1 US 2001006966 A1	25-03-2002 15-08-2001 29-12-1999 29-12-1999 22-08-2001 04-04-2001 05-07-2001
WO 9204011	A 19-03-1992	US 5156850 A AT 108999 T AU 648822 B2 AU 8500091 A CA 2088376 A1 DE 69103153 D1 DE 69103153 T2 DK 546038 T3 EP 0546038 A1 ES 2056660 T3 FI 930862 A IE 913023 A1 JP 2796433 B2 JP 6500774 T KR 162106 B1 MX 9100838 A1 NO 930604 A NZ 239574 A PT 98802 A , B WO 9204011 A1 US 5785994 A US 5232705 A ZA 9106802 A	20-10-1992 15-08-1994 05-05-1994 30-03-1992 01-03-1992 01-09-1994 24-11-1994 28-11-1994 16-06-1993 01-10-1994 25-02-1993 11-03-1992 10-09-1998 27-01-1994 01-12-1998 01-04-1992 26-02-1993 26-10-1993 31-12-1993 19-03-1992 28-07-1998 03-08-1993 27-05-1992
WO 9200729	A 23-01-1992	AT 116845 T	15-01-1995

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No. . . . .

PCT/CH 03/00523

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9200729	A	AU 652169 B2	18-08-1994
		AU 8204791 A	04-02-1992
		CA 2046448 A1	13-01-1992
		DE 69106709 D1	23-02-1995
		DE 69106709 T2	11-05-1995
		DK 538335 T3	19-06-1995
		EP 0538335 A1	28-04-1993
		ES 2069897 T3	16-05-1995
		FI 930097 A	11-01-1993
		IE 912373 A1	15-01-1992
		JP 2948906 B2	13-09-1999
		JP 5508844 T	09-12-1993
		MX 9100118 A1	01-09-1992
		NO 930032 A	15-01-1993
		NZ 238867 A	26-08-1993
		PT 98252 A , B	29-05-1992
		WO 9200729 A1	23-01-1992
		ZA 9105274 A	29-04-1992